143-LB: Changes in Perceptions and Confidence of Health Care Professionals across Medical Specialties Regarding Use of SGLT2 and GLP-1 for Cardiorenal Benefit in Type 2 Diabetes

Sodium-glucose cotransporter (SGLT2) inhibitors and glucagon like peptide 1 (GLP-1) receptor agonists have been demonstrated to provide cardio-renal benefits in patients with type 2 diabetes (T2D). Little is known about confidence and perceptions of healthcare professionals (HCPs) across medical specialties to utilize these agents in clinical practice. An online survey was conducted among a national sample of 1,006 physicians, nurse practitioners, and physician assistants in cardiology, endocrinology, nephrology, and primary care. They were asked about current and past perceptions and confidence in prescribing SGLT2s and GLP-1s for cardio-renal benefit. Survey results were analyzed using weighting for gender, region, and practice type. Participants were 56% male, 53% had >10 years of experience, and 32% saw >100 patients/month with T2D. Two-thirds of HCPs reported greater confidence now in prescribing SGLT2s compared to one year ago, with highest proportions among cardiologists (77%) and nephrologists (76%). Over half of HCPs (55%) were more confident now compared to one year ago with prescribing GLP-1s. A greater proportion of participants felt HCPs across all specialties are more responsible now for prescribing SGLT2s and GLP-1s compared to one year ago. Specifically, cardiologists (84%) and nephrologists (76%) felt their own specialties are now responsible for prescribing these agents for cardio-renal protection. These results suggest confidence to prescribe SGLT2s and GLP-1s for cardio-renal benefit has recently increased among medical specialties involved in T2D care. Lower HCP confidence to prescribe GLP-1s compared to SGLT2s may be due to the injectable mode of administration for GLP1s. These results also indicate a growing perception that prescribing these agents is not just the responsibility of a single specialty but is a shared responsibility across the T2D care team. Disclosure D. Zytnick: None. R. Woolley: None. M. Bruns: None. C. M. Shay: None.